1. Understand utilization management (UM) criteria required for approval of PCSK9 inhibitors.
2. Guidance as to meeting UM so as to increase chance of success and reduce time for patient access to PCSK9 inhibitors.
3. Provide knowledge of additional LDL-C lowering agents in later stage clinical development which may impact their
management in the near future.
04/26/2019 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Evan Stein, MD, PhD